Gilead Sciences (GILD) — Q2 2026 Earnings Preview

1. Earnings Preview

Key Takeaway: The setup into Q2 is moderately constructive — consensus is a manageable bar, Yeztugo is the primary swing factor, and the underlying business is outperforming despite large IPR&D charges clouding reported EPS. The biggest wildcard is whether BIC/LEN received FDA approval in August and any early color on launch trajectory.

Heading into Q2 2026, the consensus bar is manageable: total revenue of ~$7.41B implies ~4.7% YoY growth, well within the trajectory set by Q1's beat and the subsequent $400M raise to full-year guidance. Management's tone is notably confident — HIV total sales guidance was raised to ~8% YoY growth (from ~6% in February), and Yeztugo guidance was lifted to ~$1B for FY2026, potentially achieving blockbuster status in its first full year. Estimate revisions have been remarkably stable post-Q1 earnings, with only modest upward drift on Yeztugo, suggesting the Street has high conviction in the guidance framework and is not pricing in meaningful upside or downside. The stock has underperformed significantly since Q1 earnings — down ~2.2% vs XBI up ~10.2% and SPY up ~3.6% — driven by the reported EPS miss (large IPR&D charges from three acquisitions) and the EVOKE-03 discontinuation in NSCLC, meaning the stock is not pricing in a beat and any positive surprise on Yeztugo or HIV could be a catalyst. The single biggest wildcard is the BIC/LEN FDA decision expected in August 2026: approval and any early payer access commentary would be a meaningful positive catalyst, while any delay or label restriction would weigh on the HIV pipeline narrative; a Trodelvy first-line TNBC FDA decision update (expected H2 2026) is the secondary wildcard.

2. KPIs & Consensus Expectations

Key Takeaway: Consensus is a manageable bar on revenue (~$7.41B vs $6.96B actual in Q1 2026), with Yeztugo the biggest swing factor. HIV total revenue and Trodelvy are the two most watched KPIs heading into the print.

Table 1 — Q2 2026 Current Quarter Snapshot

Note: Non-GAAP EPS for Q2 2026 is heavily distorted by ~$9.50/share in acquired IPR&D charges from the Arcellx, Ouro Medicines, and Tubulis acquisitions. Underlying EPS ex-IPR&D ($8.45–$8.85 FY2026 guidance) is the more relevant metric for assessing business performance.

Table 2 — Beat/Miss History (Last 8 Quarters, Top 2 KPIs)

Pattern: GILD has beaten total revenue consensus in 7 of the last 8 quarters, with HIV consistently outperforming. The one miss (Q1 2025, -2.2%) was modest. HIV revenue has beaten consensus in 6 of the last 8 quarters, with the two misses being marginal (-0.4% and -0.7%). This track record supports a constructive setup heading into Q2 2026.

3. Guidance & Commentary Evolution

Key Takeaway: Guidance was raised meaningfully at Q1 2026 earnings on May 7, 2026 — HIV growth raised to ~8% YoY and Yeztugo to ~$1B. No material post-earnings guidance revisions have been disclosed. Management tone is confident, with commercial outperformance expected to offset incremental deal-related R&D costs.

4. Guidance vs. Estimate Revision Tracker

Key Takeaway: Estimates for Q2 2026 and FY2026 have been remarkably stable since Q1 earnings, with only modest upward drift on Yeztugo. Consensus is tracking in line with raised guidance, suggesting the Street has high conviction in the framework and is not pricing in meaningful upside or downside.

The slight upward drift in Yeztugo FY2026 consensus above the $1B guidance midpoint reflects growing Street confidence in the launch trajectory. Trodelvy estimates have drifted modestly higher, likely reflecting NCCN Category 1 designation pull-through ahead of the expected 1L TNBC FDA decision in H2 2026.

5. Stock Performance

Key Takeaway: GILD is down ~2.2% since Q1 earnings (May 7) vs XBI up ~10.2% and SPY up ~3.6% — a meaningful underperformance driven by the reported EPS guidance miss (large IPR&D charges) and the EVOKE-03 discontinuation in NSCLC. The stock has not priced in a beat, creating an asymmetric setup if Q2 results and BIC/LEN launch commentary are positive.

GILD vs XBI (Biotech ETF) vs S&P 500 (SPY) — Indexed to 100 at Q1 2026 Earnings (May 7, 2026). Source: Yahoo Finance.

Sector ETF: XBI (SPDR S&P Biotech ETF) is used as the sector benchmark, appropriate for GILD's biopharmaceutical sub-sector.

Key Events Since Q1 2026 Earnings

• May 22, 2026 — Hepcludex FDA Accelerated Approval: First and only approved treatment for chronic hepatitis delta virus (HDV) infection in the US; approval based on Phase 3 MYR301 data. New liver disease revenue stream.
• June 8, 2026 — ISLEND-1/2 Positive Topline (ISL/LEN Weekly Oral HIV): Both Phase 3 studies met primary efficacy endpoint at Week 48; ISL/LEN demonstrated non-inferiority to Biktarvy and standard-of-care daily oral regimens; no treatment-emergent resistance. Gilead leads US commercialization. Validates the weekly oral HIV treatment opportunity.
• June 9, 2026 — EVOKE-03 Discontinued (Trodelvy + KEYTRUDA in 1L NSCLC): Trial did not meet the bar per Merck commentary. Negative for Trodelvy’s lung ambitions; core TNBC thesis unaffected. Merck’s competing sac-TMT TROP2 ADC is advancing in lung.
• August 2026 (Expected) — BIC/LEN FDA Decision: Bictegravir + lenacapavir once-daily oral for virally suppressed HIV under priority review; launch targeted for late August; modest 2026 revenues with meaningful ramp in 2027. Key near-term catalyst.

6. Material News & Developments

Key Takeaway: The most important development since Q1 earnings is the positive ISLEND-1/2 readout for weekly oral ISL/LEN, which validates Gilead’s HIV pipeline and sets up a meaningful new revenue stream from 2027. The EVOKE-03 discontinuation is a modest negative for Trodelvy’s lung ambitions but does not change the core TNBC thesis.

• June 8, 2026 — ISLEND-1/2 Positive Topline (ISL/LEN Weekly Oral HIV Treatment): Both Phase 3 studies met primary efficacy endpoint at Week 48; ISL/LEN demonstrated non-inferiority to Biktarvy and standard-of-care daily oral regimens; no treatment-emergent resistance to either islatravir or lenacapavir; Gilead leads US commercialization (60/40 cost share, 50/50 revenue split up to $2B then 65/35 Gilead/Merck). Implication: Validates the weekly oral HIV treatment opportunity; positions GILD to capture switch patients currently going to non-Gilead regimens; modest 2026 revenue, meaningful ramp from 2027.
• May 22, 2026 — Hepcludex FDA Accelerated Approval (Chronic HDV): First and only approved treatment for chronic hepatitis delta virus infection in the US; approval based on Phase 3 MYR301 data; confirmatory long-term outcomes study already initiated. Implication: New revenue stream in liver disease; modest near-term contribution but strategically important.
• June 9, 2026 — EVOKE-03 Discontinued (Trodelvy + KEYTRUDA in 1L NSCLC): Trial did not meet the bar per Merck commentary; Merck framed this as “not all TROP2 ADCs are the same.” Implication: Negative for Trodelvy’s lung ambitions; however, core TNBC thesis (1L approval expected H2 2026) is unaffected. Merck’s competing sac-TMT TROP2 ADC is advancing in lung.
• August 2026 (Expected) — BIC/LEN FDA Decision: Bictegravir + lenacapavir once-daily oral for virally suppressed HIV under priority review; launch targeted for late August; modest 2026 revenues with meaningful ramp in 2027. Implication: Key near-term catalyst; any color on launch readiness or payer access will be closely watched on the Q2 call.
• Arcellx Acquisition Closed April 28, 2026: Full ownership of anito-cel (PDUFA December 23, 2026); revenue expected to begin early 2027; iMMagine-3 enrollment nearly complete; management targeting ~200 authorized treatment centers before year-end. Implication: Largest cell therapy launch by ATC count; $3.5B 4L+ CAR-T market opportunity; potential filing for 2L expansion as early as 2027.
• Tubulis Acquisition Closed May 21, 2026 / Ouro Medicines Closed June 4, 2026: Adds TUB-040 NaPi2b ADC (platinum-resistant ovarian cancer) and gamgertamig BCMA-CD3 T cell engager (autoimmune diseases). Implication: Expands ADC and inflammation pipelines; registrational studies in autoimmune diseases targeted as early as 2027; combined three acquisitions carry ~$11.8B in acquired IPR&D charges for FY2026.
• Merck AIDS Investor Event (August 3, 2026): Merck presented detailed ISL/LEN Phase 3 data at AIDS 2026; confirmed Gilead leads US commercialization; Merck’s wholly-owned ISL/neferine weekly oral also advancing with Phase 3 (Symphoria) expected to open H1 2027. Implication: Competitive read-through — Merck’s own weekly oral program is a longer-term competitive threat but ISL/LEN is the near-term opportunity for GILD.

7. Peer Commentaries — Read-Throughs for Q2 2026

Key Takeaway: The most relevant peer read-throughs for GILD’s Q2 2026 are: (1) MRK’s AIDS Investor Event confirming ISL/LEN Phase 3 success and Gilead’s US commercialization lead; (2) BMY’s Q2 2026 earnings showing strong cell therapy demand (Breyanzi +41%) and multiple myeloma momentum, relevant context for anito-cel’s upcoming launch; (3) AZN’s Q2 2026 earnings showing TROP2 ADC competitive dynamics and TNBC market evolution; (4) MRK’s ASCO Investor Event showing sac-TMT advancing in TNBC and endometrial cancer, a competitive read for Trodelvy.

HIV / PrEP — Merck AIDS Investor Event (August 3, 2026)

Read-through: POSITIVE for GILD

• MRK presented positive Phase 3 data from ISLEND-1 and ISLEND-2 at AIDS 2026: ISL/LEN once-weekly oral demonstrated non-inferiority to Biktarvy (ISLEND-1) and standard-of-care daily oral regimens (ISLEND-2); viral suppression rates above 90–95% at Week 48; no treatment-emergent resistance to either islatravir or lenacapavir; well tolerated with safety profile comparable to standard of care.
• Gilead leads US commercialization; Merck leads ex-US; 60/40 cost share, 50/50 revenue split up to $2B then 65/35 Gilead/Merck.
• MRK sized the HIV treatment market at ~$26B today growing to ~$32B by mid-2030s; PrEP market at ~$4B expected to more than double; long-acting regimens expected to represent the “solid majority” of patients by mid-2030s.
• MRK’s own wholly-owned ISL/neferine weekly oral (Symphoria Phase 3 opening H1 2027) is a longer-term competitive threat but does not affect near-term ISL/LEN opportunity.
• MRK’s monthly oral PrEP (Ala, MK-8527) Phase 3 readout expected 2027 — potential future PrEP competitor to Yeztugo.
• Implication for GILD Q2: Validates the HIV long-acting oral opportunity; ISL/LEN launch readiness and payer access commentary will be key on the Q2 call. Any update on BIC/LEN (FDA decision expected August) will also be closely watched.

Multiple Myeloma / Cell Therapy — BMY Q2 2026 Earnings (July 30, 2026)

Read-through: MIXED for GILD (anito-cel context)

• BMY’s Breyanzi (CD19 CAR-T) posted 41% growth in Q2 2026, driven by best-in-class profile and strong demand across approved indications in both US and international markets — positive read for overall CAR-T market demand.
• BMY’s Iberdomide (CELMoD, oral) has an August 17, 2026 PDUFA date; BMY expects strong adoption in the community (70–80% of MM patients treated in community); Iberdomide is positioned to replace Pomalyst/Revlimid in leading triplet regimens in second line. Mezigdomide (Phase 3 positive data) has NDA accepted with PDUFA May 13, 2027.
• BMY’s CELMoD class (oral agents) is positioned as a different modality from CAR-T — they are complementary rather than directly competitive with anito-cel in 4L+, but could compete in earlier lines.
• Implication for GILD Q2: Strong CAR-T market demand (Breyanzi +41%) is a positive read for anito-cel’s eventual launch. BMY’s oral CELMoD agents entering 2L+ could affect the competitive landscape for anito-cel’s line expansion ambitions.

TNBC / ADC / Oncology — AZN Q2 2026 Earnings (July 27, 2026)

Read-through: MIXED for GILD (Trodelvy context)

• AZN’s Dashaway (TROP2 ADC) launched in TNBC patients not candidates for immunotherapy following US approval; AZN describes its TROP2 ADC as “best in class” due to stable linker design, showing differentiated activity with higher response rates, PFS, and OS in 1L TNBC.
• AZN’s Enhertu continues to hold market leadership in HER2-positive and HER2-low breast cancer — not directly competitive with Trodelvy (TNBC focus) but relevant for overall breast cancer market dynamics.
• AZN’s oncology total revenues grew 15% in H1 2026 with 18% US growth — positive read for overall oncology market demand.
• Implication for GILD Q2: AZN’s TROP2 ADC launch in TNBC is a competitive read for Trodelvy. However, Trodelvy’s 1L TNBC FDA decision is still expected H2 2026 and NCCN Category 1 designation is already in place. The key question is whether AZN’s launch is taking share in the TNBC market ahead of Trodelvy’s 1L approval.

TROP2 ADC Competitive Dynamics — MRK ASCO Investor Event (June 1, 2026) & Goldman Sachs Conference (June 9, 2026)

Read-through: MIXED for GILD (Trodelvy competitive context)

• MRK’s sac-TMT (TROP2 ADC, Kelun partnership) showed positive Phase 3 data in endometrial cancer (TroFuse-005 — first TROP2 ADC to show OS and PFS benefit vs chemotherapy in endometrial cancer) and positive Phase 3 data in NSCLC (OptiTROP-Lung05 in China).
• MRK explicitly noted EVOKE-03 (Trodelvy + KEYTRUDA in 1L NSCLC) “didn’t meet the bar” and framed this as “not all TROP2 ADCs are the same” — reinforcing sac-TMT’s differentiation vs Trodelvy in lung.
• MRK’s sac-TMT is being evaluated in 7+ tumor types; OptiTROP-Breast03 showed positive results in 1L TNBC (Kelun data).
• Implication for GILD Q2: sac-TMT’s advancing data in TNBC and endometrial cancer is a competitive read for Trodelvy. However, Trodelvy’s 1L TNBC FDA decision (H2 2026) and NCCN Category 1 designation provide near-term commercial protection. The EVOKE-03 discontinuation removes Trodelvy’s lung ambitions but does not affect the core TNBC thesis.

Immunology / Drug Pricing — ABBV Q2 2026 Earnings (July 31, 2026)

Read-through: NEUTRAL for GILD

• ABBV raised FY2026 revenue guidance by $300M (total $600M raise since start of year); Skyrizi ($5.5B, +24%) and Rinvoq ($2.5B, +24%) continue to outperform — positive read for overall biopharma commercial execution.
• ABBV noted payer contracting negotiations are “tough but consistent with prior years” with “low single digit concessions around rebates and price concessions” in immunology — relevant context for GILD’s HIV payer dynamics.
• ABBV’s multiple myeloma pipeline (BCMA-CD3 T cell engager “intent”) advancing in 2L+ and newly diagnosed MM — longer-term competitive read for anito-cel’s line expansion.
• Implication for GILD Q2: ABBV’s strong commercial execution is a positive read for biopharma sector. Payer dynamics commentary is relevant context for GILD’s HIV franchise.

8. Insider Transaction Activity

Key Takeaway: All insider transactions since Q1 earnings are pre-planned 10b5-1 sales — no discretionary open-market buys or sells. The pattern is consistent with routine planned selling and does not signal any unusual insider conviction in either direction.

All transactions are pre-planned 10b5-1 sales. No open-market discretionary buys or sells. No unusual clustering or size. Nothing notable from an insider signal perspective.